Skip to main content
OpenTrials
Completed

NCT Number: NCT03450265

Hemopatch Compared to TachoSil in Postoperative Air Leak Duration After Pulmonary Resection

This study is a randomized, controlled study, with the primary objective to demonstrate non-inferiority of Hemopatch compared to TachoSil in postoperative air leak duration after pulmonary resection, and with the secondary objective of evaluating the safety of Hemopatch compared to TachoSil.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Baxter Investigational Site, Catania, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Preoperative-

  • Patients, 18 years or older at the time of signing the informed consent form (ICF), undergoing elective pulmonary resections (lobectomy, segmentectomy, or wedge resection), either through open thoracotomy or through Visually Assisted Thoracotomy surgery (VATS)
  • Patients or legally authorized representatives, who are able to give IC after an explanation of the proposed study, and who are willing to comply with the study requirements for therapy during the entire study treatment period
  • If female of child-bearing potential, patient will present with a negative blood/urine pregnancy test, and will agree to employ adequate birth control measures for the duration of the study

Intraoperative-

  • Patients with grade 1 or 2 (Macchiarini scale) air leakage after primary stapling and limited suturing

Exclusion criteria

Preoperative-

  • Patients who had previous lung surgery (on the same side)
  • Patients with an active, florid infection
  • Patients who have received chemotherapy within the previous 3 weeks.
  • Patients who have received radiation therapy within the previous 4 weeks.
  • Patients with known hypersensitivity to the components of the investigational product and control (human fibrinogen, human thrombin, collagen of any origin, NHS-PEG)
  • Patients undergoing emergency surgery
  • Female patients of childbearing potential with a positive pregnancy test or intent to become pregnant during the clinical study period
  • Female patients who are nursing
  • Patients with exposure to another investigational drug or device clinical trial within 30 days prior to enrollment or anticipated in the 30 day study period till the End of study visit.
  • Patient has a clinically significant concurrent medical condition (e.g. concomitant illness, drug/alcohol abuse) that, in the opinion of the investigator, could adversely affect patient's safety and/or compliance with study procedures
  • Patient is a family member or employee of the investigator

Intraoperative-

  • Patients with serious complications during surgery, including the need for adhesiolysis, and pneumonectomy.
  • Patients who were treated with any surgical sealant
  • Major intraoperative complications that require resuscitation or deviation from the planned surgical procedure
  • Patients with any other intraoperative findings identified by the surgeon that may preclude the conduct of the study procedure

Treatment and study plan

HEMOPATCH

Device

Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.

Tachosil

Device

Applied according to the current instruction for use (IFU).

Primary outcomes

  1. Duration of postoperative air leakage

    Time frame: Day 1 to Day 30

Secondary outcomes

  1. Incidence of intraoperative treatment failure

    Time frame: Day 1

  2. Incidence of patients with prolonged air leakage defined as air leakage > 5 Days

    Time frame: Day 5 to Day 30

  3. Number of additional procedures needed

    Time frame: Day 1 to Day 30

    Type of procedures include chest drainage, re-operation, respiratory assistance, and blood transfusion

  4. Time to chest tube removal

    Time frame: Day 1 to Day 30

  5. Time in surgery (minutes) from incision to closure

    Time frame: Day 1

  6. Length of stay in hospital (days)

    Time frame: Day 1 to Day 30

  7. Number of unplanned interventions

    Time frame: Day 1 to Day 30

  8. Incidence of pre-defined postoperative Adverse Events of Special Interest (AESIs)

    Time frame: Day 1 to Day 30

    Pre-defined AEs include Pneumothorax, Bronchopleural fistula, Emphysema (subcutaneous and mediastinal), Pleural effusions, Postoperative respiratory failure, Empyema, Allergic reactions in reasonable temporal relationship with the product application

  9. Number of patches used intra-operatively

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Baxter Healthcare Corporation

Industry

Registry information

Official study title

A Randomized, Controlled, Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Mar 1, 2018
Registry last updated
Apr 6, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.